Search

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more

Publications

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

EHA Congratulates EHA Research Grants 2022 Recipients

The Hague, May 30, 2022 – EHA congratulates eight talented researchers in hematology on their receipt of the EHA Research Grants 2022 after a rigorous selection process.

Read more

Mission ‘Gene Therapy’ for Horizon Europe

Mission ‘Gene Therapy’ for Horizon Europe

Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.

Read more

GAPP Joint Action

Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.

Read more

Mini-hormone fights iron

Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.

Read more

EHA in EU-funded project on voluntary plasma collection capacity in Europe

EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)

Context: Plasma shortage 

Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…

Read more